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A number of trials have studied the value of aromatase inhibitors (AIs) for the adjuvant treatment of early hormone-responsive
postmenopausal breast cancer. Three different AIs have been used and they have been compared as initial treatment (two trials) or
after 2–3 years of tamoxifen (four trials), in both cases against a standard arm of 5 years of tamoxifen. In addition, two trials have
evaluated AIs against no treatment after 5 years of tamoxifen. In all circumstances, the AIs have demonstrated superior efficacy.
However, no results are currently available for the key question, that is – is it better to start initially with an AI or use it sequentially
after 2 years of tamoxifen? Here, we review the trial results and present two models, which address this issue. The models clearly
show that early treatment with an AI is superior to using it after 5 years of tamoxifen. They also favour an upfront strategy to
sequencing after 2 years of tamoxifen, but in this case the differences are small and model-dependent. A key question is whether AIs
have substantially better efficacy than tamoxifen for ER-positive–PgR-negative tumours, where the data are currently contradictory.
A mechanism explaining why greater efficacy might be so is proposed. Further results from ongoing trials will be needed to resolve
this issue.
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BACKGROUND
Several trials have shown that the aromatase inhibitors (AIs)
achieve a lower recurrence rate than tamoxifen when used as
adjuvant treatment for post-menopausal women with hormone-
receptor-positive breast cancer. Interpretation of these results is
complicated by the fact that three different AIs have been used,
and also that they have been offered at different times in the
treatment programme. Three types of schedule can be identified:
initial treatment; sequencing treatment after 2–3 years of
tamoxifen; and extended treatment after 5 years of tamoxifen.
Larger reductions in the hazard ratio for recurrence have been
reported in the sequencing and extended treatment regimens, but a
proper evaluation of the overall impact on recurrence needs to
account for the higher recurrence rates that occurred in the period
before switching to an AI.
Here, we briefly review the design and findings of these trials
and use the results to develop models, which can be used to
explore the long-term (10 year) impact of different approaches.
The two types of model used are: (i) a surface model, which uses
the available data in the most straightforward way to predict
outcomes; and a so-called ‘deep’ model which tries to explain the
current data by an underlying mechanistic model. The goal of this
later model is to try to explain and understand at a biologic level
what has been observed. If correct, it may provide more accurate
long-term predictions of recurrence rates. The model also
identifies some key questions that should be amenable to study
in the current trials.
METHODS
End points
Several end points could be used in evaluating the different
strategies. Recurrence is the most sensitive endpoint for evaluating
efficacy, and includes distant recurrence, local recurrence and
contralateral tumours. This is preferable to disease-free survival
(DFS), which would also include intercurrent deaths without
recurrence. These latter events rightfully belong in the safety or
overall analysis, but are not relevant for efficacy, where they dilute
real differences in efficacy with events unrelated to breast cancer.
Using only distant recurrences would provide a better surrogate
for death from breast cancer, but their use requires longer follow-
up, and it is too early to use this end point at this stage.
The use of recurrence rates gives equal weight to early and late
recurrences. It is clear that an early recurrence is more detrimental
than a late one, and integrating the recurrence curves to give the
per cent of ‘time lost to recurrence’ is probably the best summary
measure of efficacy in this context. Thus a recurrence at year 1
would lose 90% of the first 10 years to recurrence, but a recurrence
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www.bjcancer.comat year 9 would only lose 10%. For a 10-year window, the actual
number of years lost is just the percentage multiplied by 10, and
this gives a useful measure for comparing strategies. We will
evaluate both measures, but focus on this latter outcome measure
below.
Carryover
One key question is how long the effect will be maintained after
treatment is stopped. The EBCTCG overview has shown that the
effect of tamoxifen on recurrence is maintained for about 5 years
after stopping 5 years of treatment (Early Breast Cancer Trialists’
Collaborative Group, 2005). The only data on AIs come from the
ATAC trial where the same magnitude of reduction was seen in
year 6 as in previous years (ATAC Trialists’ Group, 2005).
Carryover is a consequence of curing a proportion of patients,
and not simply holding tumours in check. If treatment is curative,
then all future recurrences are prevented, so the hazard ratio will
remain below unity even after treatment has stopped. This is
expected for chemotherapy, but the long-term results from the
overview strongly suggest that tamoxifen is also curing a
proportion of patients, and that its action is more than cytostatic.
A reasonable assumption is that the early superiority of AIs over
tamoxifen will result in a higher cure rate and that the reduction in
recurrence rates will also be maintained for 5 years after the
treatment ceases. This assumption is used in our base case model.
However, given the importance of this parameter and the paucity
of data, models with a 2-year carryover are also evaluated.
Available trial data
The reported adjuvant trials have used three different AIs in three
different settings. The key parameters for the different trials are
summarized in Table 1. Trials are grouped into initial treatment
trials, sequencing or switching trials, and extended treatment
trials. Where available, hazard ratios are given (or estimated)
separately according to progesterone receptor (PgR) status. We
first estimated baseline recurrence rates for oestrogen receptor
(ER)-positive patients treated with 5 years of tamoxifen. The
hazard rates for recurrence are known to peak in the second year
of follow-up and then decline. We have used the results of the
ATAC to model these rates in the first 6 years, giving annual rates
of 1.5, 3.8, 2.6, 2.9, 2.5, and 3.1 per cent for years 1–6, respectively.
The overview data have then been used for years 7–10 and a
constant rate of 2.4%year
 1 provides an excellent fit to these data
(Early Breast Cancer Trialists’ Collaborative Group, 2005).
Initial treatment trials
The hazard ratio for anastrozole in the ATAC trial was 0.74. (ATAC
Trialists’ Group, 2005) and for letrozole in the BIG1-98 trial was
0.72 (BIG1–98 Collaborative Group, 2005), suggesting a similar
overall effect. We have used an HR of 0.73 in our analysis.
Sequencing trials
For studies of the use of an AI after 2–3 years of tamoxifen, hazard
rates of 0.70 have been reported for the IES study using
exemestane (Coombes et al, 2004a,b), 0.60 for the ABCSG8/
ARNO95 trial (Jakesz et al, 2005a) and 0.46 for the latest update of
the much smaller Italian trial using anastrozole in node-positive
women only (Boccardo et al, 2005). In this model, we have given
equal weight to the two large trials and assumed a hazard ratio of
0.65 beginning after 2 years of tamoxifen.
Extended treatment trials
The MA-17 trial was the first trial to report on the use of an AI
(letrozole) after 5 years of tamoxifen (Goss et al, 2003, 2005).
Although intended for a 5-year period of use, the trial was stopped
early with a 29-month median follow-up and a hazard ratio of 0.57.
Recently an Austrian study (ABCSG Trial 6a) has also reported on
the randomization to 3 years of anastrozole vs placebo after 5 years
of tamoxifen (with or without aminoglutethemide). They found a
hazard ratio of 0.64 for extended treatment (Jakesz et al, 2005b).
We have taken an average effect of 0.60, and assume this effect will
persist for the full treatment period plus a carryover period as
above.
For these trials, the treatment period extends beyond 5 years, so
a fairer comparison would be against initial AI or sequencing
strategies of the same duration. However, by assuming a 5-year
carryover effect, this will have little impact on the results for the
first 10 years.
RESULTS
Surface model
The results predicted from this model are shown in Figure 1 and
Table 2 for the first 10 years of follow-up. Table 2 also gives results
for a 2-year carryover period. For a 5-year carryover period, the
absolute reduction in recurrence rate at 10 years is 5.6% for initial
use of an AI compared to 5 years of tamoxifen (22.9 vs 17.3%),
Table 1 Adjuvant trials of AIS
Trial AI Sample size Median follow-up (months)
Hazard ratio for recurrence (and 95% CIs where available)
All ER+ ER+/PgR+ ER+/PgR 
Initial treatment for up to 5 years
ATAC
b,c ANA 5216
# 68 0.74 (0.64–0.87) 0.84 (0.69–1.02) 0.43 (0.31 –0.61)
BIG 1–98
d LET 8028 26 0.72 (0.61–0.86) 0.72
a 0.72
a
Switching after 2–3 years vs continued tamoxifen for 5 years
IES
e,f EXE 4742 31 0.70 (0.58–0.83) 0.72
a* 0.63**
ITA
g ANA 448 52 0.43 (0.25–0.73) — —
ABCSG8/ARNO
h ANA 3224 28 0.60 (0.44–0.81) 0.66 (0.46–0.93) 0.42 (0.19–0.92)
Extended treatment vs placebo after 5 years of tamoxifen
MA-17
i,j LET 5157 29 0.57 (0.43–0.75) — —
ABCSG 6a
k ANA 856 60 0.64 (0.41–0.99) — —
aBased on similar DFS (0.84 vs 0.83). **Based on DFS values of 0.66 vs 0.58 in the earlier analysis
e;
#HR +ve pts. ANA – anastrozole, LET – letrozole, EXE – exemestane.
bATAC
Trialists’ Group, 2005.
cDowsett et al, 2005.
dBIG 1–98 Collaborative Group, 2005.
eCoombes et al, 2004a.
fCoombes et al, 2004b.
gBoccardo et al, 2005.
hJakesz et al, 2005a.
iGoss et al, 2003.
jGoss et al, 2005.
kJakesz et al, 2005b.
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average time lost to recurrence is reduced by 3.1% or 3.7 months.
The model predicts a similar recurrence rate at 10 years for the
strategy of switching to an AI after 2 years compared as to initial
use (Figure 1A); but, because the benefits occur later, there are still
more years of life lost to recurrence with this strategy (Figure 1B,
9.6 vs 9.0%, corresponding to a 0.7 month difference). Waiting 5
years before commencing an AI is not an effective strategy;
although for women who have already received 5 years of
tamoxifen, it is more effective than stopping treatment.
PgR subgroups
Some but not all trials have suggested that the benefit of AIs over
tamoxifen is particularly apparent in the ER-positive but PgR-
negative subgroup. This was particularly apparent in the ATAC
trial where the hazard ratio was 0.43 for PgR  patients (n¼880)
and 0.83 for PgRþ patients (n¼3834) (Dowsett et al, 2005).
Smaller differences in this direction were seen in the ARNO/
ABCSG trial again using anastrozole, where the effect on PgR 
tumours (n¼564) was again very large (HR¼0.42) (Jakesz et al,
2005a), and to a lesser extent in the IES trial using exemestane
(Coombes et al, 2004a). However, no differences were seen in the
early report of the BIG 1–98 trial using letrozole (Table 1). Data on
PgR subgroups are not available for the other trials.
If one uses a hazard ratio of 0.43 for anastrozole for ERþ/PgR 
patients, as reported in both the ATAC and ABCSG8/ARNO95
studies (ATAC Trialists’ Group, 2005; Jakesz et al, 2005a), the
indication for using an AI initially in the subgroup is very strong,
with very large gains both in 10 year recurrence rates (16.3 vs 20.2
vs 34.0%) and total time lost to recurrence (8.5 vs 12.3 vs 18.4%),
leading to gains of 4.6 and 11.9 months, respectively, when
compared with sequencing after 2 years of tamoxifen or use of
tamoxifen only.
Concomitant with a greater effect of anastrozole in the ERþ/
PgR  group in the ATAC trial is a less extreme hazard ratio in the
ERþ/PgRþ group of 0.84 (Dowsett et al, 2005). If this is a true
estimate of the difference in this subgroup and the hazard ratio for
an AI starting after 2 years of tamoxifen is 0.65 and after 5 years is
0.60, then a switching strategy after 2 years dominates an AI
upfront strategy for this subgroup, both in terms of recurrence
rates at 10 years (15.2 vs 13.2%) and time lost to recurrence (0.6
months difference; Table 2). Both of these regimens still dominate
a strategy of waiting 5 years to commence use of an AI in terms of
time lost to recurrence (Table 2).
However, purely statistical ‘surface models’ can be unreliable for
long-term extrapolation, and a more biologic ‘deep model’
suggests a somewhat different picture, especially for the ERþ/
PgRþ subgroup.
Deep model
In the ATAC trial, PgR-negative patients had a particularly poor
outcome if treated with tamoxifen. This is in keeping with other
studies in which PgR negativity is a poor prognostic variable in
tamoxifen-treated patients (Bardou et al, 2003). In addition, Gross
et al (1984) have shown that loss of PgR was an early indicator of
progression in tamoxifen-treated patients with metastatic disease.
Table 2 Recurrence rates at 10 years and ‘time lost to recurrence’ in first 10 years (%) assuming no intercurrent mortality for four different treatment
strategies and either a 2 year or 5 year carryover effect
Recurrence(%) Time lost (%)
Carryover
(years) Initial AI
Tam 2 years
+ AI 3 years
Tam 5 years
+ AI 5 years Tam 5 years Initial AI
Tam 2 years
+ AI 3 years
Tam 5 years
+ AI 5 years Tam 5 years
All ER+ 2 18.9 19.2 18.9 22.9 9.3 9.9 11 12.1
5 17.3 17.1 18.9 22.9 9 9.6 11 12.1
ER+/PgR  2 21.9 25.5 25.8 34 9.4 13.2 16.3 18.4
5 16.3 20.2 25.8 34 8.5 12.3 16.3 18.4
ER+/PgR+ 2 16 15 15 17.8 7.7 7.3 8.2 9
5 15.2 13.2 15 17.8 7.6 7.1 8.2 9
Deep model 2 20.3 21.3 21.2 24.5 9.6 10.5 11.6 12.5
(20% PgR ) 5 18.1 19.1 21.2 24.5 9.2 10.2 11.6 12.5
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Figure 1 Proportion of oestrogen-receptor-positive women who will
develop recurrence (A) and time lost to recurrence (B) in the first 10 years
of follow-up for four different treatment strategies using the ‘surface model’
and a 5 year carryover effect: aromatase inhibitor for 5 years; 2 years of
tamoxifen followed by 3 years of an AI; 5 years of tamoxifen followed by 5
years of an AI; and 5 years of tamoxifen alone. See text for parameter
estimates.
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of micro metastases from PgRþ to PgR  during tamoxifen
treatment. If this were true, the differences seen with sequential
treatment would not represent ‘tamoxifen priming’, which is
difficult to understand, but would reflect a drift towards
progesterone-receptor negativity and a more rapid development
of resistance with this drug. A simple Markov model using two
compartments, based on PgR status and hypothesizing a transition
from PgRþ to PgR  in the micro metastases with tamoxifen
treatment and a higher recurrence rate in PgR-negative women
receiving tamoxifen could explain these data. This is illustrated in
Figure 2. In particular, we assume the transition from PgRþ to
PgR  is 10%year
 1 for 4 years and that recurrence rates are the
same for AIs or tamoxifen when the phenotype of the micro
metastases is ERþ/PgRþ (nominally 2%year
 1), but is twice as
high on tamoxifen (4%year
 1), but unchanged for an AI
(2%year
 1), when the current phenotype is ERþ/PgR . This
leads to the results shown in Figure 3 and Table 2 when 20% of the
patients are PgR-negative at the outset. A good fit to the observed
data and surface model is obtained for the first 6 years, but this
model does not predict a long-term benefit for the switching
strategy.
In particular, this model suggests that it is better to use an AI
first since the effect of using tamoxifen is not to prime patients, but
to shift a proportion of them to a phenotype which will progress
more rapidly if left on tamoxifen.
CONCLUSIONS
It must be remembered that these predictions are model-based and
will require empirical confirmation. The difference in averaged
hazard ratios between the upfront and switching strategies is not
statistically significant when a heterogeneity test is employed. In
addition to the uncertainties in the estimates of the individual
hazard ratios, a more important source of uncertainty is the
accuracy of the structural model for extrapolation beyond
currently available follow-up times, and the lack of direct
comparisons of an AI upfront vs a sequencing strategy. The deep
model nicely explains the findings of the ATAC and ABCSG8/
ARNO95 trials (ATAC Trialists’ Group, 2005; Jakesz et al, 2005a),
where the relative benefit of anastrozole compared to tamoxifen is
the same for PgR-negative patients, regardless of when it is started.
It also predicts a greater apparent benefit for anastrozole after 2
years of tamoxifen in PgR-positive women because in this period
some of these women would have been shifted into a PgR-negative
phenotype where tamoxifen would have been particularly less
effective. Again, this accords well with the observed data in these
trials, and emphasizes the need to consider the whole follow-up
period, not just the follow-up after switching, as has been done in
the current sequencing trials. The greater benefit of an AI in ERþ/
PgR  patients compared to ERþ/PgRþ tumours was significant
in the ATAC trial (Dowsett et al, 2005), and was supported by the
ABCSG/ARNO trial (Jakesz et al, 2005a) and to some extent by the
IES trial (Coombes et al, 2004b). However, the relatively small
number of patients in the ERþ/PgR  subgroup and the apparent
lack of difference of effect according to PgR status in BIG 1–98
indicate that these predictions need further empirical validation. It
is possible that the lack of heterogeneity in the BIG 1–98 trial
reflects a difference in the AIs, but the most likely explanation for
this phenomenon is a differential effect of tamoxifen in these two
subgroups. Bardou et al (2003) have found that PgR negativity is
an indicator of poor prognosis in tamoxifen-treated women, and
this is in accord with several reports that HER-2-positive patients
(which are more likely to be PgR-negative) do less well on
tamoxifen. However, the EBCTCG overview (Early Breast Cancer
Trialists’ Collaborative Group 2005) results do not indicate this
differential effect in tamoxifen-treated women. This could represent
dilution due to heterogeneous and less accurate receptor measure-
ments in the overview, but again this requires further explanation.
If PgR is predictive, then initial use of an AI is clearly indicated
for PgR-negative tumours. For PgR-positive tumours, there is
more uncertainty, but initial use of an AI, for say 3 years, may still
be better than sequencing it after 2 years of tamoxifen, as this is the
period with highest recurrence rates. It also avoids the side effects
associated with tamoxifen. Trials comparing these two approaches
would be highly desirable.
Direct evidence for a phenotype shift, especially in tamoxifen-
treated patients may be obtainable by comparing recurrent disease
with the primary cancer or monitoring PgR status in peripheral
blood as has been done for HER-2 (Meng et al, 2004).
Recently Punglia et al (2005) have published a model of similar
structure to our surface model, but it has important differences in
detail, which led them to the conclusion that a switching strategy is
optimal. A major difference is that they have used a mixture of end
points – DFS for the ATAC, IES BIG 1–98 and ITA trials, but time
to recurrence for MA-17 and ABCSG8/ARNO95. These end points
are not interchangeable and because of the dilutionary effect of
deaths without recurrence when using DFS, this approach will
exaggerate the benefits of a switching strategy. Even DFS is defined
ER+/PgR+ ER+/PgR−
Clinical 
recurrence
2% per year 2% per year on AI
4% per year on 
tamoxifen
10% per year 
for 4 years
Phenotypic 
change
(tamoxifen only)
Figure 2 Schematic representation of the ‘deep model’. Patients with
ERþ/PgRþ develop recurrence at a rate of 2%year
 1 while the
micrometastases retain this phenotype, regardless of whether treated by
tamoxifen or an AI, but tamoxifen-treated patients transition to the ERþ/
PgR  phenotype at a rate of 10%year
 1 for 4 years. Patients with an
ERþ/PgR  phenotype (either initially or after transition) have twice the
recurrence rate on tamoxifen (4 vs 2%year
 1).
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Figure 3 Proportion of oestrogen-receptor-positive women who will
develop recurrence in the first 10 years of follow up for four different
treatment strategies using the ‘deep model’ and a 5 year carryover effect,
assuming 20% of the patients are initially ERþ/PgR : aromatase inhibitor
for 5 years; 2 years of tamoxifen followed by 3 years of an AI; 5 years of
tamoxifen followed by 5 years of an AI; and 5 years of tamoxifen alone. See
text for parameter estimates.
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include any (nonbreast) cancer, but the others do not). For these
reasons and the ones stated in the Methods section, time-to-
recurrence is the most appropriate end point for these analyses.
Punglia et al (2005) also explore ‘carryover’ effects in which AIs are
assumed to do worse than tamoxifen after both treatments have
stopped. This unlikely scenario also leads to a more unfavourable
outcome for the initial use of AIs.
Our assumptions on carryover do not have a major effect for the
first 10 years of follow-up, except for the extended treatment
strategies, which would appear more favourable if there was no
carryover. Of course, the duration of treatment is longer here, and
a fairer comparison would be against upfront or sequencing
strategies with the same duration of treatment. If this were done,
the model again predicts that an AI upfront strategy is optimal.
Optimal duration of treatment with an AI is a key outstanding
question for which there are currently no data. Hopefully this will
be addressed in future trials.
Currently, there are also no data for the key comparison of an AI
upfront vs sequencing after tamoxifen. The BIG 1–98 trial is
scheduled to provide such data in 2008 for letrozole and the TEAM
study will have data for exemestane, but this is likely to mature
even later.
These gaps in our knowledge provide the rationale for the
modelling we have done, but again we emphasize that models
should be used as interim measures to guide current thinking and
practice. They will be superseded by the actual trial data once it
becomes available.
Acceptability and side effects are also part of an overall
evaluation. Overall, the AIs are better tolerated than tamoxifen,
with fewer hot flushes, gynaecologic symptoms, and thromboem-
bolic events, but more joint symptoms and fractures (Coombes
et al, 2004a; ATAC Trialists’ Group, 2005; BIG 1–98 Collaborative
Group, 2005). For most women, this would favour using an AI
initially, but the differential side-effect profiles may lead to
different decisions in individual cases.
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